BeOne Medicines AG (ONC)

BeOne Medicines AG Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	513.02	286.93	-644.79	-881.71	-2,004	-1,458
Depreciation & Amortization	150.03	141.69	171.76	87.68	66.28	46.46
Stock-Based Compensation	538.73	510.86	441.62	367.62	303.16	240.71
Other Adjustments	-56.13	-2.79	47.94	-360.5	5.37	-9.73
Change in Receivables	-208.39	-164.95	-329.44	-188.31	304.11	-423.02
Changes in Inventories	-168.99	-93.17	-91.5	-140.95	-56.69	-153.33
Changes in Accounts Payable	69.21	79.83	121.5	21.48	-4.35	20.01
Changes in Accrued Expenses	347.3	311.76	111.35	180.11	45.63	140.04
Changes in Unearned Revenue	-	1.29	0.63	-255.59	-151.82	407.7
Changes in Other Operating Activities	39.35	56.13	30.29	12.71	-4.49	-109.75
Operating Cash Flow	1,285	1,128	-140.63	-1,157	-1,497	-1,299
Operating Cash Flow Growth	505.99%	-	-	-	-	-
Capital Expenditures	-170.22	-185.84	-492.66	-561.9	-325.43	-262.94
Purchases of Intangible Assets	-10.69	-80.69	-36.47	-34.37	-143.67	-51.91
Purchases of Investments	-	-11.83	-19.01	-14.9	-15.91	-2,191
Proceeds from Sale of Investments	1.67	3.45	2.66	673.24	1,564	3,147
Other Investing Activities	1.35	-1.24	-2.86	-2.08	-1.49	-
Investing Cash Flow	-199.72	-276.16	-548.35	60	1,077	640.66
Short-Term Debt Issued	211.88	233.68	868.27	661.53	313.77	406.45
Short-Term Debt Repaid	-871.86	-1,045	-704.22	-309.58	-417.08	-321.75
Net Short-Term Debt Issued (Repaid)	-659.98	-811.11	164.05	351.95	-103.31	84.7
Long-Term Debt Issued	850.59	850.59	9.05	22.5	37.37	16.84
Long-Term Debt Repaid	-41.66	-39.72	-28.03	-13.69	-	-
Net Long-Term Debt Issued (Repaid)	808.92	810.86	-18.98	8.81	37.37	16.84
Issuance of Common Stock	156.8	196.28	45.37	55.71	46.96	3,535
Net Common Stock Issued (Repurchased)	156.8	196.28	45.37	55.71	46.96	3,535
Other Financing Activities	10.65	863.41	3	-	-	-
Financing Cash Flow	1,162	1,059	193.45	416.48	-18.97	3,637
Effect of Exchange Rate Changes on Cash and Cash Equivalents	75.86	60.02	-51.71	-8.08	-69.38	14.04
Net Cash Flow	2,323	1,971	-547.24	-689.05	-507.85	2,993
Free Cash Flow	1,115	941.74	-633.29	-1,719	-1,822	-1,562
Free Cash Flow Growth	18.36%	-	-	-	-	-
FCF Margin	19.42%	17.63%	-16.62%	-69.93%	-128.68%	-132.76%
Free Cash Flow Per Share	9.73	8.30	-6.01	-16.47	-17.67	-16.83
Levered Free Cash Flow	928.65	598.39	-648.34	-1,177	-2,501	-1,268
Unlevered Free Cash Flow	803.79	619.48	-835.99	-1,946	-2,260	-1,370

Updated May 6, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q